Browse studies

Find your next paid study

54 recruiting studies matching your filters

Newest first Highest paying

Phase 2

KYSA-6: A Phase 2/3, Open-Label, Randomized, Controlled, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-cell (CD19 CAR T) Therapy, Versus Ongoing Standard-Of-Care Immunosuppressive Therapy in Patients With Generalized Myasthenia Gravis

A Study of the Anti-CD 19 Chimeric Antigen Receptor T Cell Therapy for Patients with Myasthenia Gravis

Myasthenia GravisGeneralized Myasthenia Gravis

Estimated

~$10 – $8,750

Kyverna TherapeuticsNCT06193889

Phase 1

Descartes-08 for Children, Adolescents and Young Adults With Childhood-onset Systemic Lupus Erythematosus, ANCA-associated Vasculitis, Juvenile Myasthenia Gravis, and Juvenile Dermatomyositis

Safety, tolerability and efficacy of Descarte-08 in children, adolescents and young adults with childhood-onset systemic lupus erythematosus, ANCA-associated v…

Childhood-onset Systemic Lupus ErythematousANCA-Associated Vasculitis (AAV)Juvenile Myasthenia Gravis+1 more

Estimated

~$10 – $8,750

Cartesian TherapeuticsNCT07089121

Phase 3

Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

The purpose of this study is to evaluate the efficacy and safety of nipocalimab compared to placebo in participants with generalized myasthenia gravis (gMG). T…

Myasthenia Gravis

Estimated

~$10 – $8,750

Janssen Research & Development, LLCNCT04951622

Phase 2

An Open-label, Single-arm Study Evaluating the Activity, Safety, and Pharmacokinetics of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis

The purpose of the study is to assess the safety and tolerability of subcutaneous (sc) administration of rozanolixizumab in pediatric participants aged ≥2 to \…

Generalized Myasthenia Gravis

Estimated

~$10 – $8,750

UCB Biopharma SRLNCT06149559

Phase 3

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study With an Open-label Extension Period to Evaluate the Efficacy and Safety of Telitacicept in Patients With Generalized Myasthenia Gravis

The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of generalized myasthenia gravis.

Generalized Myasthenia Gravis

Estimated

~$10 – $8,750

Vor BiopharmaNCT06456580

Quantification of Change in MG Disease Activity in Individuals With Generalized Myasthenia Gravis (gMG) After Administration of VYVGART® or VYVGART Hytrulo® Using BioDigit MG

Evaluate the feasibility of using digital health technologies to monitor disease symptoms over time in individuals with gMG who are initiating treatment with V…

Myasthenia Gravis Generalized

Estimated

~$10 – $1,125

BioSensicsNCT07226830

Phase 4

A Phase 4, Open-Label, Prospective, Single-Group, Multicenter Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adult Participants With New-Onset Generalized Myasthenia Gravis

The main purpose of this study is to measure how well adults with new-onset gMG (which means they've had generalized disease signs and/or symptoms for less tha…

New Onset Generalized Myasthenia Gravis (gMG)

An Open-Label, Single-arm Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, and Efficacy of Gefurulimab in Pediatric Patients (6 to < 18 Years of Age) With Generalized Myasthenia Gravis (gMG) Who Express Acetylcholine Receptor Antibodies (AChR+)

The primary objective of this study is to assess the pharmacokinetics and pharmacodynamics of gefurulimab in pediatric participants with AChR+ gMG for the dura…

Generalized Myasthenia GravisgMG

Estimated

~$10 – $8,750

Alexion Pharmaceuticals, Inc.NCT06607627

Phase 4

OCTAGON: A Phase 4, Single Arm Study to Investigate Oral Corticosteroid Tapering in Adult Patients With Generalized Myasthenia Gravis Treated With Ravulizumab

This is a prospective, multicenter single arm study designed to evaluate the effectiveness and safety of a predefined oral corticosteroids (OCS) tapering sched…

Generalized Myasthenia GravisgMG

Estimated

~$10 – $8,750

Alexion Pharmaceuticals, Inc.NCT07221838

Observational

Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults withNeuromuscular Disease

This single-arm pilot study evaluates the effects of whole-body electrical muscle stimulation (WB-EMS) exercise on neuromuscular and physical function in adult…

Neuromuscular Diseases (NMD)Amyotrophic Lateral SclerosisMyasthenia Gravis+15 more

Estimated

~$10 – $6,250

University of Missouri-ColumbiaNCT07478172

Observational

The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis: a Validation Study

ME\&MG is a standalone software (digital solution) running on patients smartphones, connected to a web portal for physicians. It is intended to be used as an u…

Myasthenia Gravis

Estimated

~$10 – $7,500

Ad scientiamNCT05564936

Observational

Light vs. Moderate Intensity Exercise in Individuals With Myasthenia Gravis

The overall purpose of this pilot study is to examine the feasibility, acceptability, and tolerability of light and moderate intensity exercise in adults with …

Myasthenia Gravis

Estimated

~$10 – $7,500

HealthPartners InstituteNCT06491238